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It is estimated that 65–70% of the susceptibility
to schizophrenia can be attributed to a genetic
component.1 Even though schizophrenia is highly
heritable, genetic linkage studies have failed to
establish a common chromosomal region linked
with this disorder. This suggests that multiple genes
combine to cause the disorder and that each factor
confers only a small degree of risk for the disease.2
Multiple lines of evidence implicate dopami-
nergic system dysfunction in the pathogenesis 
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Background/Purpose: The Val108/158Met (rs4680) single nucleotide polymorphism (SNP) in the catechol-
O-methyltransferase (COMT) gene contributes to genetic susceptibility to schizophrenia, which is specifi-
cally related to impairments in executive functioning. A different genomic region composed of three SNPs
(rs737865, rs4680, rs165599) within the COMT gene has been reported to be significantly associated
with schizophrenia in Ashkenazi Jews. This study aims to clarify the association between these three SNPs
and their haplotypes with schizophrenia and neurocognitive functioning, using both case-control and
family-based designs.
Methods: The case-control study included 124 schizophrenia patients and 112 healthy controls, while the
family samples included 83 families with at least two affected siblings. The neurocognitive functioning
was assessed by the Continuous Performance Test (CPT) and Wisconsin Card Sorting Test. The association
analysis was performed using TRANSMIT and FBAT.
Results: There was no significant association between the three SNPs and schizophrenia in the case-control
study. In the family study, the A allele of rs165599 was transmitted preferentially to the affected individu-
als (p = 0.023), and significantly associated with a later age of onset (p = 0.018), more severe delusion/
hallucination symptom dimension (p = 0.027), and poorer performance in the CPT (p = 0.04). The triple
SNP haplotypes did not reveal any significant association with schizophrenia or neurocognitive function.
Conclusion: The SNP rs165599, which has been mapped to the 3-UTR region of the COMT gene, was sig-
nificantly associated with schizophrenia in our family study, and possibly associated with the age of onset,
delusion/hallucination symptom dimension, and CPT performance. Therefore, COMT may contribute to
the genetic risk for schizophrenia not through the Val108/158Met polymorphism, but through other variants
that are situated 3 to this region, in the Taiwanese population. Nevertheless, the true associated func-
tional variants in our subjects remain to be elucidated. [J Formos Med Assoc 2009;108(4):301–309]
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of schizophrenia. Therefore, the catechol-O-
methyltransferase (COMT) gene, which codes
for a principle enzyme that catalyzes the metabo-
lism of dopamine, is considered as one of the
candidate genes that contribute to the risk for
schizophrenia. Furthermore, the micro-deletion
on chromosome 22q11 region, which includes the
COMT gene and causes velocardiofacial syndrome,
is associated with a high rate of psychosis, partic-
ularly schizophrenia.3
The most commonly examined locus within
the COMT gene is a functional polymorphism at
codon 158 of the membrane-bound form of the
enzyme (Val108/158Met). The enzyme activity de-
creases to one quarter of the wild-type level in
the substituted form, which results from a G to A
transition at the single nucleotide polymorphism
(SNP) rs4680. In addition, the valine variation
has been shown to correlate with poorer execu-
tive functioning and prefrontal cortical activity,
specifically on the Wisconsin Card Sorting Test
(WCST)4,5 and the N-Back Working Memory
Task.5–7 However, not all association studies that
have examined COMT as a candidate gene for
schizophrenia have shown a positive association.
Two recent meta-analyses of case-control studies
did not support this association in European and
Asian populations.8,9
Shifman et al10 found a unique haplotype 
(G-G-G haplotype of the three SNPs, rs737865,
rs4680 and rs165599) of COMT that is highly
associated with schizophrenia in Ashkenazi Jews.
This haplotype has also been reported to be
linked with lower expression of COMT mRNA in
the human brain.11,12 Two independent studies
have reported a significant association with dif-
ferent haplotypes of a triple SNP haplotype
block.13,14 These findings imply that the genetic
association between COMT and schizophrenia
probably result from SNPs that occur in several
regions of the gene.
Previous studies of Asian populations using
case-control designs or trio samples have not
supported the association of SNP rs4680 with
schizophrenia.9,15–19 However, other COMT poly-
morphisms have been less well studied using
Asian family studies. Moreover, the association
between cognitive function and the COMT geno-
type in Asian schizophrenia patients remains un-
clear. Hence, the present study aimed to clarify
the association of three SNPs (rs737865, rs4680,
rs165599) and their haplotypes with schizophre-
nia and neurocognitive functioning, as assessed
by the Continuous Performance Test (CPT) and




The schizophrenia patients in the case-control
study were recruited from patients consecutively
admitted to the acute inpatient psychiatric wards
of the Department of Psychiatry, National Taiwan
University Hospital and the university-affiliated
hospitals of Taipei City Psychiatric Center and
Taoyuan Psychiatric Center. All patients fulfilled
the diagnostic criteria of schizophrenia according
to DSM-IV definitions. Patients with major phys-
ical and neurological illness or substance use dis-
order were excluded. After informed consent was
obtained, the study subjects received a clinical
interview for comprehensive assessment of clini-
cal features, and cross-sectional psychopathology
examination using the Positive and Negative
Syndrome Scale (PANSS)20 when they were sta-
bilized after treatment and prepared for dis-
charge. In addition, the course of illness during
index admission was recorded and whole blood
was collected. A total of 124 patients were re-
cruited in this study, and 91 received the CPT and
87 the WCST at the same time as clinical rating.
A total of 112 normal controls without a history
of psychiatric disorders were recruited, mostly
from hospital staff.
Schizophrenia probands who had at least two
affected siblings were identified from the out-
patient clinics of the Department of Psychiatry,
National Taiwan University Hospital and the 
university-affiliated Taoyuan Psychiatric Center.
Data collection was initiated after informed 
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consent was obtained from the identified study
subjects and their families. All of the family mem-
bers were personally interviewed by the research
psychiatrists using the Psychiatrist Diagnostic
Assessment (PDA).21 Clinical symptoms were rated
using the Schedule for Assessment of Negative
Symptoms (SANS)22 and the Schedule for Assess-
ment of Positive Symptoms (SAPS),23 with satis-
factory reliability. The final diagnostic assessment
was formulated by integrating the PDA data and
the clinical information from the medical chart
records. The final diagnosis was performed ac-
cording to DSM-IV criteria. The family samples
included 324 individuals with DNA available from
83 families with at least two affected siblings, and
118 individuals received the CPT and 103 the
WCST at the same time as clinical rating.
The demographic data for the case-control
study was 57% male cases and 38% male con-
trols, and the mean age was 37.5 ± 6.8 years for
the cases and 31.8 ± 7.6 for the controls. The mean
age of onset was 21.9 ± 5.5 years. In the family
study, there were 62% male subjects among the
affected individuals, with a mean age of 32.7±7.7
years, and the mean age of onset was 22.4 ± 6.3
years. The founders (i.e. parents of the probands)
were 45% male, with a mean age of 60.2 ± 8.1
years.
The clinical ratings of schizophrenia subjects
according to neuropsychological tests were as
follows. In the case-control study, the mean score
of the positive symptom subscale of PANSS was
1.95 ± 0.68, negative symptom subscale was
2.45 ± 0.93, and the general psychopathology
subscale was 1.76 ± 0.48. In the family study, the
mean score for the delusion/hallucination symp-
tom dimension of SAPS and SANS was 1.34±1.38,
the negative symptom dimension was 1.73 ± 1.53,
and the disorganization symptom dimension was
1.16 ± 1.32. The subjects in both samples were in
a relatively stable state.
CPT
A CPT machine from Sunrise Systems, v. 2.20
(Pembroke, MA, USA), was used to assess sus-
tained attention. The procedure has been described
in detail elsewhere.24 Briefly, numbers from zero
to nine were randomly presented for 50 milli-
seconds, each at a rate of one per second. Each
subject underwent two different CPT sessions
that included the undegraded 1–9 task and the
25% degraded 1–9 task. Subjects were asked to
respond whenever the number nine was pre-
ceded by the number one on the screen. During
the 25% degraded session, a pattern of snow was
used to toggle the background and foreground 
in order to distort the image. Sensitivity (d) 
was derived from the hit rate (probability of a 
response to target trials) and false-alarm rate
(probability of response to non-target trials).25
Sensitivity is an individual’s ability to discrimi-
nate target from non-target stimuli. The effect of
age, education and sex on CPT performance was
adjusted, based on a community sample of 345
subjects.24 CPT performance was calculated from
the z scores of the undegraded and degraded
CPT results, which were adjusted for these demo-
graphic features. Subsequently, the z scores of
these performance indicators were used for fur-
ther study analyses.
WCST
We employed a computerized version of the
WCST26 that had been applied in a previous
study of the Taiwanese population.27 During the
test, subjects were required to match 128 re-
sponse cards to the four stimulus cards along
one of three dimensions (color, form, number),
by pressing one of the four number keys on the
computer keyboard. Subjects were not informed
of the correct sorting principle, nor were they told
when the principle would shift during the test,
but they were given feedback (“right” or “wrong”)
on the screen after each trial. The indexes of
WCST28 used for this study were the following:
(1) perseverative errors, which reflected the ten-
dency towards perseveration; and (2) categories
achieved, which was the number of times that 10
consecutive correct responses were made, which
reflected overall success. These indicators were
found to be impaired in schizophrenia pro-
bands29,30 and in their first-degree relatives.31
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The effect of age, education and sex on WCST
performance was adjusted based on 211 healthy
screened controls (unpublished data from Sheng-
Hsiang Lin, Chih-Min Liu, Shi-Kai Liu, Institute of
Epidemiology, College of Public Health, National
Taiwan University, Taipei, Taiwan, 2008). WCST
performance was calculated as the z scores of the
perseverative errors and category achieved, which
was adjusted for these demographic features.
Subsequently, the z scores of these performance
indicators were used for further study analyses.
Genotyping
The three SNPs (rs737865, rs4680, rs165599)
were genotyped using a PCR–RFLP method. The
primers were designed using Primer 3.0 (http://
frodo.wi.mit.edu/cgi-bin/primer 3/primer 3-www.
cgi). Briefly, PCR reactions were performed with
10 ng genomic DNA, 0.5 μL of each PCR primer,
2.5 mM dNTP, and 2.5 U ProTaq DNA poly-
merase (Protech Technology Enterprise Co., Taipei,
Taiwan). Thermal cycling conditions for PCR
were as follows: 94°C for 2 minutes, followed by
35 cycles of 94°C for 45 seconds, 55°C for 30
seconds, and 72°C for 1 minute; followed by
final extension at 72°C for 5 minutes. PCR prod-
ucts were treated by the restriction enzymes
Bsc4I, NlaIII and HpaII for the rs737865, rs4680
and rs165599 genotyping, respectively. Digested
products were then subjected to electrophoresis
on an agarose gel, which was stained with ethid-
ium bromide and the bands were visualized under
ultraviolet light. DNA bands were read as follows:
for rs737865, a 245-bp band indicated uncut and
allele A, and a 163-bp band indicated cut and al-
lele G; for rs4680, a 114-bp band indicated uncut
and allele G, and a 96-bp band indicated cut and
allele A; for rs165599, a 242-bp band indicated
uncut and allele A, and a 115-bp band indicated
cut and allele G.
Statistical analysis
In order to verify the sample accuracy, including
family relationship and genotype, PEDCHECK
version 1.132 and UNKNOWN version 5.2333
were used to check the patterns of Mendelian 
inheritance, and the procedure ALLELE of SAS/
GENETICS version 8.2 was used to test for the
Hardy-Weinberg equilibrium. The allele and
genotype frequency were calculated and com-
pared by a χ2 test in the case-control study. Single
loci and haplotype associations were tested by
TRANSMIT34 and FBAT.35 The association between
SNP genotype and neuropsychological function
was tested by the Kruskal-Wallis test in the case-
control study and by haplotype FBAT35 in the
family study. Linkage disequilibrium (D) was
calculated with the Gold program.36
Results
All three SNPs tested in this study (rs737865,
rs4680, rs165599) were compatible with the
Hardy-Weinberg equilibrium in the case-control
and family studies.
Case-control study
In the case-control study, G allele frequency
among the cases was 0.29 for the SNP rs737865,
0.76 for rs4680, and 0.45 for rs165599. This was
compared to controls with a G allele frequency
of 0.25 for SNP rs737865, 0.75 for rs4680, and
0.48 for rs165599. There was no significant dif-
ference between the cases and controls for allele
or genotype comparisons.
Family study
In the family study, the founder G allele frequency
was 0.24 for the SNP rs737865, 0.79 for rs4680,
and 0.48 for rs165599. The A allele of rs165599
was transmitted preferentially to affected indi-
viduals, shown by different statistical methods, as
demonstrated by TRANSMIT (p = 0.023) and FBAT
(p=0.039). The detailed results are listed in Table 1.
Haplotype association analysis
The D values of two SNPs are listed in Table 2.
All the D values were lower than 0.7. Haplotype
association analysis is shown in Table 3. The
triple SNP haplotype did not reveal a significant
association with schizophrenia as shown by 
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different statistical methods. The highly signifi-
cant haplotype G-G-G in Ashkenazi Jews,10 and
the A-G-A polymorphisms in an Irish study of
high-density schizophrenia families13 were not
significantly associated with schizophrenia in our
studies.
Phenotype analysis
In the case-control study, the three SNPs and
their haplotypes were not associated with the
symptom profiles, age of onset, or CPT and WCST
performance. In the family study, the A allele of
SNP rs165599 was significantly associated with
poorer performance in the degraded CPT (p=0.04),
with a later age of onset (p = 0.018), and with 
a more severe delusion/hallucination symptom
dimension (p = 0.027), which was calculated by
the sum of the global scores for Delusion and
Hallucination in the SAPS. The other two SNPs
and all the triple SNP haplotypes were not asso-
ciated with age of onset, symptom profiles, or
CPT and WCST performance. The details are
listed in Table 4.
Discussion
Our case-control study revealed no association
between the three SNPs in COMT and schizo-
phrenia. We found that the A allele of the SNP
rs165599, which was located in the 3-UTR re-
gion of the COMT gene, was significantly over-
transmitted to the affected individuals in our
family study, and was significantly associated
with a later age of onset, more severe delusion/
hallucination symptom dimension, and poorer
performance for the degraded CPT. In addition,
the triple SNPs haplotypes were not significantly
associated with schizophrenia in our subjects.
The functional polymorphism of Val108/158 Met
(rs4680) was not associated with schizophrenia
in either our case-control or family study. These
results were compatible with previous case-control
Association of 3 region of COMT with schizophrenia
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Table 1. Single locus association analysis using TRANSMIT and FBAT in the family samples
SNP Polymorphism*
Minor allele TRANSMIT FBAT
frequency N χ2 p N Z p
rs737865 A/G 0.24 82 0.10 0.75 24 0.94 0.34
rs4680 G/A 0.21 81 0.10 0.76 21 −0.29 0.77
rs165599 A/G 0.48 78 5.14 0.023† 24 2.07 0.039†
*Second allele under oblique line (/) is the minor allele; †A allele is the over-transmitted allele. SNP = single nucleotide polymorphism.
Table 2. Linkage disequilibrium (D) between the two studies’ single nucleotide polymorphisms
Case-control study Family study
rs737865 rs4680 rs165599 rs737865 rs4680 rs165599
rs737865 … …
rs4680 0.470 … 0.100 …
rs165599 0.471 0.652 … 0.253 0.414 …
Table 3. Haplotype association analysis using
TRANSMIT
Haplotype HF χ2 p
A-G-A 0.22 0.01 0.92
G-G-A 0.12 1.71 0.19
A-A-A 0.15 0.68 0.41
G-A-A 0.04 0.03 0.86
A-G-G 0.37 1.96 0.16
G-G-G 0.07 0.14 0.71
A-A-G 0.03 0.40 0.53
G-A-G 0.003 0.11 0.74
HF = haplotype frequency.
studies of Asian subjects.9,16,17,19,37–39 Interestingly,
the allele frequencies of this polymorphism were
similar among most Asian subjects and very dif-
ferent from those in European subjects.9,40
We reported no significant association with the
triple SNP haplotypes for the case-control or
family study, which was consistent with the neg-
ative results previously reported in case-control
studies of Asian populations.17,39,41 Among stud-
ies of European subjects, different populations
have been reported to exhibit an association be-
tween schizophrenia and the different triple SNP
haplotypes. Examples of this include the G-G-G
haplotype in Ashkenazi Jews,10 the A-G-A haplo-
type in Irish families,13 and the A-A-G haplotype in
Australian family samples.14 The D values among
the three SNPs in our study were much lower than
those in the European subjects and much closer
to those of the Chinese Han subjects.39 The failure
to replicate the triple SNP haplotype association
in the Han population might reflect a differential
linkage disequilibrium structure for the COMT
gene, which arises from ethnic differences.
In this study, we found that SNP rs165599,
but not the functional variant rs4680 or the triple
SNP haplotypes, was associated with a diagnosis
of schizophrenia, delusion/hallucination symp-
tom dimension, age of onset, and CPT perfor-
mance. This finding was different from other
case-control association studies in Asian popu-
lations.17,39,41 Furthermore, the association with
rs165599 was shown exclusively in our family
study, but not in our case-control study, which
implied that this association might be specific to
the samples with higher genetic loading. The
function of SNP rs165599 has been explored in
several studies. Bray et al11 demonstrated that
COMT is subject to allelic differences in expres-
sion level in the human brain. Specifically, the 
3 flanking region of SNP rs165599 exhibited
significant differences in allelic expression, with
lower relative expression if the G allele is at
rs165599. This implies that the A allele at
rs165599 in schizophrenia patients is associated
with higher expression of the COMT gene, which
is compatible with Egan et als hypothesis of hy-
pofrontality in schizophrenia.4 It has been reported
that rs4680 interacts with SNP rs2097603 at the
P2 promoter region and SNP rs165599 in the 3
region. These interactions have been implicated
Y.L. Chien, et al
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Table 4. Phenotype analysis of three single nucleotide polymorphisms using haplotype FBAT in the 
family study
rs737865-A* rs4680-G* rs165599-A*
N Z p N Z p N Z p
Age of onset 38 0.566 0.578 31 −0.458 0.647 39 2.364 0.018
Delusion/hallucination 31 0.815 0.415 24 −1.527 0.127 29 2.205 0.027
symptom dimension†
Negative symptom 37 1.446 0.148 30 −0.876 0.381 31 1.810 0.070
dimension†
Disorganization symptom 33 1.356 0.175 29 −0.373 0.709 26 1.059 0.290
dimension†
d’ of undegraded CPT 19 −0.704 0.481 16 1.422 0.155 16 −1.451 0.147
d’ of degraded CPT 18 −0.564 0.573 16 0.735 0.462 15 −2.054 0.040
Perseverative errors 17 1.036 0.300 14 −1.409 0.159 15 −0.023 0.981
of WCST
Category achieved 17 −1.002 0.316 14 0.985 0.324 15 0.038 0.970
of WCST
*Major allele of the SNP; †the delusion/hallucination symptom dimension was calculated by the sum of global scores of Delusions and
Hallucinations in the SAPS; the disorganization symptom dimension was calculated by the sum of global scores of Positive Formal
Thought Disorder and Bizarre Behavior in the SAPS; the negative symptom dimension was calculated by the sum of global scores of
Affective Blunting, Alogia, Avolition–Apathy, and Anhedonia–Asociality in the SANS. N = family number.
in predicting an inefficient prefrontal working
memory response during a working memory par-
adigm in healthy control subjects.7 Recently,
there have been numerous studies that have fo-
cused on the role of RNAi, which demonstrates
that the 3 end of RNA transcripts may play a role
in regulation of the transcriptomes. Whether
rs165599 itself, or other functional variants in
tight linkage disequilibrium with this SNP, con-
tributes to the association demonstrated in the
present study needs to be further elucidated.
An association between the functional SNP
rs4680 and neurocognitive functioning has 
been reported in several studies, including with
the WCST,5,42 Letter Number Sequencing,42 N-
back,6,7 and performance on the attention do-
main of a neurocognitive battery.43 However, our
study failed to replicate the previously observed
association of this polymorphism with WCST
and CPT performance. In addition, there have
been few studies that have explored the associa-
tion between the other SNPs within the COMT
gene and neurocognitive function. Chan et al 
reported that SNP rs165599 is associated with 
visual reproduction, Stroop test, and 2-back 
reaction time for correct responses, but not with
CPT in a relatively small Chinese sample.44 Our
study is believed to be the first to show that the
3 variant of COMT may be associated with CPT
performance.
The effects of the rs4680 genotypes on clini-
cal phenotypes have been inconsistent across 
different studies. One study has reported an as-
sociation with more negative symptoms and a
younger age of onset,45 but several others have
reported no evidence of such an association.37,46
The association of rs165599 with clinical pheno-
type has been less well studied previously. Our
family study is believed to be the first to show
that SNP rs165599 is associated significantly with
a later age of onset, and a more severe delusion/
hallucination symptom dimension. The associa-
tion with delusion/hallucination symptom di-
mension in our family study seemed contradictory
to the association between COMT and hypofron-
tality reported by Egan et al,4 which implied a
lower function of dopamine in the prefrontal
lobe in schizophrenia. On one hand, it has been
found that the subcortical hyperdopaminergic
function, which is considered to contribute to
positive symptoms, is secondary to the pre-
frontal hypodopaminergic function.47 On the
other hand, we observed that rs165599 is associ-
ated with the negative symptom dimension,
with borderline significance (p = 0.07) (Table 4).
This was still consistent with the association be-
tween COMT and hypofrontality. However, this
seems to conflict with the association of SNP
rs165599 with schizophrenia with higher genetic
loadings and later age of onset. Some studies
have suggested that high familial loading is 
associated with early onset of schizophrenia.48
However, ascertainment bias49 and heterogeneity
in age of onset have also been reported.50 Whether
higher familial loading is associated with earlier
onset of schizophrenia remains inconclusive. Also,
there was no significant difference in age of onset
between our family study (22.4±6.3 years) and
case-control study (21.9 ± 5.5 years).
Although a positive association was found in
the family study, the results should be inter-
preted with caution, and we cannot exclude the
possibility of false-positivity or multiple-testing
problems. Moreover, the sample size was rela-
tively small and the power may have been in-
adequate for detecting this small genetic effect.
Another limitation is that we did not adjust for
the clinical factors, such as age of onset, when
analyzing the genetic effects on neurocognitive
function. Nevertheless, our findings implied that
the COMT gene possibly contributed to genetic
risk for schizophrenia in a higher genetic-loading
sample, and the associated locus was not the
Val108/158Met variant but other variants 3 to this
region. The true functional variants associated
with schizophrenia in our studies remain to be
clarified. It will be worthwhile to map the 3 re-
gion of the COMT gene in a larger Asian family
study, and to find the ethnicity-specific functional
variants that contribute to the genetic association
with schizophrenia and its influence on the
function of the COMT gene.
Association of 3 region of COMT with schizophrenia
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